Microstructural analysis of severe bone lesions in seven thalassemic patients treated with deferoxamine

Calcified Tissue International

Volumn 67, Issue 2, 2000, Pages 128-133

  De Sanctis, V ^b   Savarino, L ^a   Stea, S ^a   Cervellati, M ^a   Ciapetti, G ^a   Tassinari, L ^a   Pizzoferrato, A ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Bone lesions; Bone microstructure; Deferoxamine; Microhardness; Microradiography; Thalassemia; X ray diffraction

Indexed keywords

DEFEROXAMINE MESYLATE;

ADOLESCENT; ARTICLE; BONE ATROPHY; BONE LESION; BONE MINERALIZATION; BONE RADIOGRAPHY; BONE STRUCTURE; CHONDRODYSPLASIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METAPHYSIS; MICRORADIOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; THALASSEMIA; TIBIA;

EID: 0033854146     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223001122     Document Type: Article

References (35)

1. Bone disease in children with omozygous β-thalassemia
2. Transfusion requirements and effects in patients with thalassemia major
3. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
4. Growth velocity monitoring of the efficacy of different therapeutic protocols in a group of thalassemic children
5. Effect of age at start of iron chelation therapy on gonadal function in beta-thalassemia major
6. The ototoxicity of deferoxamine mesylate
7. Growth failure and bony changes induced by deferoxamine
8. Effects of deferoximine on chondrocyte alkaline phosphatase activity: Proxidant role of deferoximine in thalassemia
9. Growth, puberty and endocrine functions of beta-thalassemia major
10. Spinal deformities in deferoxamine-treated homozygous beta-thalassemia major patients
11. Growth and development in thalassemia major patients with severe bone lesions due to deferoxamine
12. Growth plate injury of the long bones in treated beta-thalassemia
13. Deferoxamine-induced bone dysplasia in patients with thalassemia major
14. Deferoxamine-induced growth retardation in patients with thalassemia major
15. Limb deformity and metaphyseal abnormalities in thalassemia major
16. Long-term follow-up study on growth and development in patients with thalassemia major who have severe bone lesions due to deferoxamine treatment
17. X-ray diffraction of newly formed bone close to alumina or hydroxyapatite-coated femoral stem
18. X-Ray diffraction standards for calcium oxide, β tricalcium phosphate, α tricalcium phosphate, tetracalcium phosphate and hydroxyapatite, respectively
19. Profile fitting for quantitative analysis in X-ray powder diffraction
20. The powder method in x-ray crystallography
21. Crystallographic lattice refinement of human bone
22. A model for bone hardness
23. The morphology of bone mineral crystals
24. Can adrenarche influence the degree of osteopenia in thalassemic children?
25. Short stature and failure of pubertal development in thalassaemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonatropin secretion
26. The morbidity of bone disease in thalassemia
27. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
28. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia
29. A multicenter safety trial of the oral iron chelation deferiprone
30. The microscopic hardness of bone
31. Trace metals and fluoride in bones and teeth
32. Relationship among carbonate apatite solubility, crystallite size, and microstrain parameters
33. Iron distribution in thalassemic bone by energy loss spectroscopy and electron spectroscopy imaging